Metabolism and Chronic Inflammation: The Links Between Chronic Heart Failure and Comorbidities

Abstract

Heart failure (HF) patients often suffer from multiple comorbidities, such as diabetes, atrial fibrillation, depression, chronic obstructive pulmonary disease, and chronic kidney disease. The coexistance of comorbidities usually leads to multi morbidity and poor prognosis. Treatments for HF patients with multi morbidity are still an unmet clinical need, and finding an effective therapy strategy is of great value. HF can lead to comorbidity, and in return, comorbidity may promote the progression of HF, creating a vicious cycle. This reciprocal correlation indicates there may be some common causes and biological mechanisms. Metabolism remodeling and chronic inflammation play a vital role in the pathophysiological processes of HF and comorbidities, indicating metabolism and inflammation may be the links between HF and comorbidities. In this review, we comprehensively discuss the major underlying mechanisms and therapeutic implications for comorbidities of HF. We first summarize the potential role of metabolism and inflammation in HF. Then, we give an overview of the linkage between common comorbidities and HF, from the perspective of epidemiological evidence to the underlying metabolism and inflammation mechanisms. Moreover, with the help of bioinformatics, we summarize the shared risk factors, signal pathways, and therapeutic targets between HF and comorbidities. Metabolic syndrome, aging, deleterious lifestyles (sedentary behavior, poor dietary patterns, smoking, etc.), and other risk factors common to HF and comorbidities are all associated with common mechanisms. Impaired mitochondrial biogenesis, autophagy, insulin resistance, and oxidative stress, are among the major mechanisms of both HF and comorbidities. Gene enrichment analysis showed the PI3K/AKT pathway may probably play a central role in multi morbidity. Additionally, drug targets common to HF and several common comorbidities were found by network analysis. Such analysis has already been instrumental in drug repurposing to treat HF and comorbidity. And the result suggests sodium-glucose transporter-2 (SGLT-2) inhibitors, IL-1β inhibitors, and metformin may be promising drugs for repurposing to treat multi morbidity. We propose that targeting the metabolic and inflammatory pathways that are common to HF and comorbidities may provide a promising therapeutic strategy.

Ginkgo biloba in the Aging Process: A Narrative Review

“…As a result of the metabolism, several conditions, such as infections, stress, inflammation exposure, radiation, and smoke, produce reactive oxygen species (ROS). When the endogenous antioxidant system or the intake of exogenous antioxidants is insufficient, these molecules can lead to irreversible cell damage and are associated with various diseases, such as diabetes, obesity, hypertension, CVD, cataracts, neurodegenerative diseases, and cancer [33][34][35][36]. Several antioxidants can help to prevent the impact of the aging process.…”

Pro-inflammatory cytokines in chronic cardiac failure: state of problem

“…Эта ассоциация указывает на существование общих патофизиологических процессов. В механизмах типовых патологических процессов важную роль играет хроническое воспаление, которое может являться связующим звеном между СН и сопутствующими заболеваниями [3].…”

The Usefulness of C-Reactive Protein to Albumin Ratio in the Prediction of Adverse Cardiovascular Events in Coronary Chronic Total Occlusion Undergoing Percutaneous Coronary Intervention

“…It has been clarified that cytokines and metabolites can be released at malnourished status. Systemic inflammation can activate immune cell transdifferentiation into pro-inflammatory and pro-fibrotic subsets, leading to cardiac hypertrophy and fibrosis ( 8 ). For instance, TNF-β as one of the most important inflammatory cytokines increased significantly in patients with malnutrition and its increase resulted in potential negative inotropic effects, worsening ventricular functions, and eventually progressing to heart failure ( 9 ).…”